Patents Assigned to Dyax Corp.
  • Nucleic acids encoding polypeptide inhibitors of human plasmin derived from the Kunitz domains
    Patent number: 8431359
    Abstract: This invention features novel proteins that are homologous to the first Kunitz domain (K1) of lipoprotein-associated coagulation inhibitor (LACI), and are capable of inhibiting plasmin and nucleic acids encoding these proteins. The invention also features the use of such proteins in therapeutic, diagnostic, and clinical methods.
    Type: Grant
    Filed: March 18, 2005
    Date of Patent: April 30, 2013
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20130078262
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 28, 2013
    Applicant: Dyax Corp.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
  • Focused libraries of genetic packages
    Patent number: 8399384
    Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: March 19, 2013
    Assignee: Dyax Corp.
    Inventor: Robert Charles Ladner
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20130045218
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 21, 2013
    Applicants: Syntonix Pharmaceuticals, Inc., Dyax Corp.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
  • NOVEL METHODS OF CONSTRUCTING LIBRARIES COMPRISING DISPLAYED AND/OR EXPRESSED MEMBERS OF A DIVERSE FAMILY OF PEPTIDES, POLYPEPTIDES OR PROTEINS AND THE NOVEL LIBRARIES
    Publication number: 20130040861
    Abstract: Methods useful in constructing libraries that collectively display and/or express members of diverse families of peptides, polypeptides or proteins and the libraries produced using those methods are disclose. Methods of screening those libraries and the peptides, polypeptides or proteins identified by such screens are also disclosed.
    Type: Application
    Filed: May 4, 2012
    Publication date: February 14, 2013
    Applicant: DYAX CORP.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • KALLIKREIN INHIBITORS AND ANTI-THROMBOLYTIC AGENTS AND USES THEREOF
    Publication number: 20130012438
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Application
    Filed: April 27, 2012
    Publication date: January 10, 2013
    Applicant: DYAX CORP.
    Inventors: Henry Blair, Thomas Beck, Robert Charles Ladner
  • KALLIKREIN-BINDING "KUNITZ DOMAIN" PROTEINS AND ANALOGUES THEREOF
    Publication number: 20120328517
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Application
    Filed: August 9, 2012
    Publication date: December 27, 2012
    Applicant: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • POLY-PEGYLATED PROTEASE INHIBITORS
    Publication number: 20120322744
    Abstract: Disclosed are compounds that comprise: (i) a Kunitz domain polypeptide that comprises a Kunitz domain that binds to and inhibits a protease; and (ii) a plurality of polyethylene glycol moieties attached to the Kunitz domain polypeptide. Each accessible primary amine of the Kunitz domain polypeptide can be attached to one of the moieties. Also disclosed are related methods.
    Type: Application
    Filed: May 3, 2012
    Publication date: December 20, 2012
    Applicant: DYAX CORP.
    Inventors: Arthur C. Ley, Aaron K. Sato, Robert C. Ladner, Mark Stochl
  • FOCUSED LIBRARIES OF GENETIC PACKAGES
    Publication number: 20120302463
    Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
    Type: Application
    Filed: August 10, 2012
    Publication date: November 29, 2012
    Applicant: Dyax Corp.
    Inventor: Robert Charles LADNER
  • Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
    Patent number: 8288322
    Abstract: A library containing a collection of genetic packages that display a member of a diverse family of peptides, polypeptides or proteins and that collectively display at least a portion of the family, the displayed peptides, polypeptides or proteins being encoded by DNA sequences containing sequences encoding a heavy chain CDR region is described.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: October 16, 2012
    Assignee: Dyax Corp.
    Inventors: Robert C. Ladner, Edward H. Cohen, Horacio G. Nastri, Kristin L. Rookey, Rene Hoet, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Kallikrein-binding “Kunitz domain” proteins and analogues thereof
    Patent number: 8283321
    Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
    Type: Grant
    Filed: October 16, 2009
    Date of Patent: October 9, 2012
    Assignee: Dyax Corp.
    Inventors: William Markland, Robert C. Ladner
  • BISPECIFIC BINDING AGENTS TARGETING IGF-1R AND ERBB3 SIGNALLING AND USES THEREOF
    Publication number: 20120244163
    Abstract: Disclosed are bispecific binding agents that specifically target both of the IGF-1 and the ErbB intracellular signaling pathways. For example, bispecific binding agents that comprise an anti-IGF-1R antibody and an anti-ErbB3 antibody connected by a linker are described herein. These bispecific agents are capable of antagonizing signal transduction by both of the IGF-1 and the ErbB signaling pathways and are useful in inhibiting the proliferation of tumor cells whose growth involves the signaling activity of both pathways.
    Type: Application
    Filed: April 10, 2012
    Publication date: September 27, 2012
    Applicants: DYAX CORP., MERRIMACK PHARMACEUTICALS, INC.
    Inventors: Birgit SCHOEBERL, Ulrik NIELSEN, Arthur J. KUDLA, Arumugam MURUGANANDAM, David BUCKLER, Alexey Alexandrovich LUGOVSKOY, Jonathan Basil FITZGERALD, Lihui XU, Neeraj KOHLI
  • Fc receptor binding proteins
    Patent number: 8273351
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: September 25, 2012
    Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
  • Focused libraries of genetic packages
    Patent number: 8258082
    Abstract: Focused libraries of vectors or genetic packages that display, display and express, or comprise a member of a diverse family of antibody peptides, polypeptides or proteins and collectively display, display and express, or comprise at least a portion of the focused diversity of the family. The libraries have length and sequence diversities that mimic that found in native human antibodies.
    Type: Grant
    Filed: September 30, 2011
    Date of Patent: September 4, 2012
    Assignee: Dyax Corp.
    Inventor: Robert Charles Ladner
  • Conformation specific antibodies
    Patent number: 8247185
    Abstract: The disclosure provides, inter alia, binding proteins (e.g., antibodies) that bind to an integrin in an activated conformation, e.g., activated LFA-1 (“aLFA-1 ”), e.g., relative to a non-activated conformation of LFA-1. In one embodiment, the binding proteins inhibit at least one function of an aLFA-1, e.g., inhibit a binding interaction between aLFA-1 and a cognate ligand of aLFA-1, e.g., an ICAM protein. The binding proteins can be used to treat or prevent an inflammatory disorder or other disorder.
    Type: Grant
    Filed: March 8, 2011
    Date of Patent: August 21, 2012
    Assignees: DYAX Corp., The CBR Institute for Biomedical Research, Inc.
    Inventors: Edward H. Cohen, Isaac J. Rondon, Timothy A. Springer, Motomu Shimaoka
  • PLASMA KALLIKREIN BINDING PROTEINS
    Publication number: 20120201756
    Abstract: Plasma kallikrein binding proteins and methods of using such proteins are described.
    Type: Application
    Filed: January 6, 2012
    Publication date: August 9, 2012
    Applicant: DYAX CORP.
    Inventor: Daniel J. Sexton
  • COMPOSITIONS AND METHODS FOR TREATING OSTEOLYTIC DISORDERS COMPRISING MMP-14 BINDING PROTEINS
    Publication number: 20120141473
    Abstract: Provided are methods and compositions for using MMP-14 or MMP-9 binding proteins alone or in combination with other therapeutic agents to treat osteolytic disorders such as osteotropic cancer and osteoporosis.
    Type: Application
    Filed: December 28, 2011
    Publication date: June 7, 2012
    Applicant: DYAX CORP.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
    Patent number: 8188045
    Abstract: Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.
    Type: Grant
    Filed: May 18, 2007
    Date of Patent: May 29, 2012
    Assignee: Dyax Corp.
    Inventors: Henry Blair, Thomas Beck, Robert C. Ladner
  • Evaluating MMP expression in patient stratification and other therapeutic, diagnostic and prognostic methods for cancer
    Patent number: 8183008
    Abstract: Provided are compositions, methods and kits for quantifying the expression and/or activity of MMP-14 and other biomarkers of cancer, which may be used diagnostically and prognostically, e.g., in patient stratification and evaluation of appropriate therapeutic regimens.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: May 22, 2012
    Assignee: Dyax Corp.
    Inventors: Clive R. Wood, Daniel T. Dransfield, Laetitia Devy
  • METALLOPROTEINASE BINDING PROTEINS
    Publication number: 20120107231
    Abstract: Proteins that bind to matrix metalloproteinase 14 and methods of using such proteins are described.
    Type: Application
    Filed: December 22, 2011
    Publication date: May 3, 2012
    Applicant: DYAX CORP.
    Inventors: Laetitia Devy, Henk Pieters, Robert C. Ladner, Rene Hoet, Daniel T. Dransfield, Clive R. Wood, Maria Henderikx